Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialist pharmaceutical company Warner Chilcott has filed a lawsuit in the US alleging that Schering AG's recently approved oral contraceptive Yaz infringes a patent that covers Warner's Loestrin 24 Fe.
Subscribe to our email newsletter
In response to news of the allegation, Schering released a statement which affirmed the company’s belief that Yaz does not infringe on the patent, and that the launch of the product will continue as planned.
Warner Chilcott is seeking treble damages, costs and a permanent injunction against Schering and its US affiliate, Berlex. The company said that it intends to launch Loestrin 24 Fe in April.
“Loestrin 24 Fe embodies a novel new dosing regimen for oral contraceptives and Warner Chilcott intends to vigorously defend our rights under our patent to oral contraceptive products delivering 24 days of active therapy,” said Roger Boissonneault, CEO of Warner Chilcott’s parent company. “In addition to recovering damages, we will seek to have Yaz removed from the market.”